This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindegardh, N.
Right arrow Articles by White, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindegardh, N.
Right arrow Articles by White, N. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1835-1836, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01534-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Importance of Collection Tube during Clinical Studies of Oseltamivir{triangledown}

Niklas Lindegardh,1,2* Geraint R. Davies,1,3 Tran Tinh Hien,4 Jeremy Farrar,2,4 Pratap Singhasivanon,1 Nicholas P. J. Day,1,2 and Nicholas J. White1,2

Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand,1 Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom,2 Wellcome Trust Centre for Clinical Tropical Medicine, University of Liverpool, Liverpool, United Kingdom,3 Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam4

Received 8 December 2006/ Returned for modification 11 January 2007/ Accepted 19 February 2007

Ex vivo conversion of the anti-influenza drug oseltamivir to its active metabolite can be inhibited by the esterase inhibitor dichlorvos or by using commercial fluoride-oxalate tubes. Oseltamivir and its active metabolite remain intact in plasma samples during a proposed virus heat inactivation step: incubation at 60°C for 45 min.

* Corresponding author. Mailing address: Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand. Phone: 66 23541395. Fax: 66 23549169. E-mail: niklas{at}tropmedres.ac

{triangledown} Published ahead of print on 26 February 2007.

Antimicrobial Agents and Chemotherapy, May 2007, p. 1835-1836, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01534-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wattanagoon, Y., Stepniewska, K., Lindegardh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tarning, J., Pongtavornpinyo, W., Fukuda, C., Singhasivanon, P., Day, N. P. J., White, N. J. (2009). Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 945-952 [Abstract] [Full Text]  
  • Holodniy, M., Penzak, S. R., Straight, T. M., Davey, R. T., Lee, K. K., Goetz, M. B., Raisch, D. W., Cunningham, F., Lin, E. T., Olivo, N., Deyton, L. R. (2008). Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid. Antimicrob. Agents Chemother. 52: 3013-3021 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»